

Antonia A Martinetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6233754/publications.pdf>

Version: 2024-02-01

66
papers

2,461
citations

186265

28
h-index

206112

48
g-index

70
all docs

70
docs citations

70
times ranked

3446
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. <i>Tumori</i> , 2021, 107, 150-159.	1.1	8
2	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	7.0	14
3	Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer. <i>Cancers</i> , 2021, 13, 2356.	3.7	26
4	Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial. <i>Oncologist</i> , 2020, 25, e460-e468.	3.7	29
5	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. <i>Cancers</i> , 2019, 11, 980.	3.7	18
6	Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?. <i>Pharmacogenomics Journal</i> , 2019, 19, 465-472.	2.0	16
7	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	2.0	12
8	Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. <i>European Journal of Cancer</i> , 2019, 107, 164-174.	2.8	9
9	Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 2166-2173.	7.0	67
10	Clinical implications for pro-GRP in small cell lung cancer. A single center experience. <i>International Journal of Biological Markers</i> , 2018, 33, 55-61.	1.8	18
11	Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 792-798.	1.0	21
12	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. <i>Annals of Oncology</i> , 2018, 29, 1800-1806.	1.2	32
13	Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017, 17, 331-336.	2.0	10
14	Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. <i>British Journal of Cancer</i> , 2017, 117, 347-352.	6.4	31
15	Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2414-2422.	7.0	148
16	Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 83-103.	1.6	10
17	IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 16887-16898.	1.8	28
18	Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. <i>Tumori</i> , 2016, 102, e11-e14.	1.1	18

#	ARTICLE	IF	CITATIONS
19	Serum soluble urokinase-type plasminogen activator receptor as a serum marker of inflammatory response that leads to tissue damage and surgical complication. <i>Wound Repair and Regeneration</i> , 2016, 24, 1036-1040.	3.0	2
20	Osteopontin, E-cadherin, and β -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	5.3	37
21	Did Circulating Tumor Cells Tell us all they Could? The Missed Circulating Tumor Cell Message in Breast Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 429-433.	1.8	26
22	Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, <i>RAS-BRAF</i> wild-type colorectal cancer receiving cetuximab or panitumumab. <i>International Journal of Cancer</i> , 2015, 137, 1467-1474.	5.1	33
23	Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8884-8895.	4.1	13
24	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 581-588.	2.4	52
25	Effect of 10-day broccoli consumption on inflammatory status of young healthy smokers. <i>International Journal of Food Sciences and Nutrition</i> , 2014, 65, 106-111.	2.8	15
26	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. <i>Cancers</i> , 2014, 6, 1753-1768.	3.7	14
27	Role of the Antiangiogenic Agent Bevacizumab in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. <i>Drugs and Aging</i> , 2011, 28, 83-91.	2.7	2
28	Effect of Broccoli Intake on Markers Related to Oxidative Stress and Cancer Risk in Healthy Smokers and Nonsmokers. <i>Nutrition and Cancer</i> , 2009, 61, 232-237.	2.0	57
29	A female survivor of childhood medulloblastoma presenting with growth-hormone-induced edema and inflammatory lesions: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 17.	0.8	3
30	Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2007, 73, 204-209.	1.9	30
31	Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion. <i>Annals of Surgical Oncology</i> , 2007, 14, 500-508.	1.5	72
32	Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Annals of Surgical Oncology</i> , 2007, 14, 2300-2308.	1.5	87
33	Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 59, 637-642.	2.3	218
34	Kit Protein (CD 117) and Proliferation Index (Ki-67) Evaluation in Well and Poorly Differentiated Neuroendocrine Tumors. <i>Tumori</i> , 2006, 92, 531-535.	1.1	13
35	Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors. <i>Cancer</i> , 2006, 107, 2474-2481.	4.1	63
36	Effect of a Tomato Drink Intervention on Insulin-Like Growth Factor (IGF)-1 Serum Levels in Healthy Subjects. <i>Nutrition and Cancer</i> , 2006, 55, 157-162.	2.0	40

#	ARTICLE	IF	CITATIONS
37	Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma. <i>Tumori</i> , 2004, 90, 535-546.	1.1	34
38	Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1006-1014.	6.3	106
39	Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole. <i>Endocrine-Related Cancer</i> , 2004, 11, 771-779.	3.1	30
40	The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients. <i>Biomedicine and Pharmacotherapy</i> , 2004, 58, 255-259.	5.6	10
41	Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer. <i>Annals of Oncology</i> , 2003, 14, 1543-1548.	1.2	51
42	Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?. <i>International Journal of Oncology</i> , 2003, 22, 1081.	3.3	3
43	Evaluation of circulating calcitonin: analytical aspects. <i>Tumori</i> , 2003, 89, 566-8.	1.1	3
44	Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. <i>Annals of Oncology</i> , 2002, 13, 1059-1066.	1.2	38
45	Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. <i>Annals of Oncology</i> , 2002, 13, 614-621.	1.2	103
46	Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002, 80, 411-418.	2.5	11
47	c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients. <i>Breast</i> , 2002, 11, 286-294.	2.2	0
48	A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. <i>Cancer</i> , 2002, 94, 299-304.	4.1	33
49	A Feasibility Study using Polychemotherapy (Cisplatin + Vindesine + Dacarbazine) plus Interferon-Alpha or Monochemotherapy with Dacarbazine plus Interferon-Alpha in Metastatic Melanoma. <i>Tumori</i> , 2001, 87, 219-222.	1.1	11
50	Diagnostic and prognostic tumor markers in the gastrointestinal tract. <i>Journal of Surgical Oncology</i> , 2001, 20, 147-166.	1.4	13
51	Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors. <i>Annals of Oncology</i> , 2000, 11, 1017-1022.	1.2	31
52	The luteinising hormone-releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 75, 65-73.	2.5	7
53	Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. <i>Cancer</i> , 1999, 86, 858-865.	4.1	249
54	Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Angeles, U.S.A.1. <i>European Journal of Cancer</i> , 1999, 35, 208-213.	2.8	65

#	ARTICLE	IF	CITATIONS
55	A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: Endocrine and clinical results. <i>Annals of Oncology</i> , 1997, 8, 649-654.	1.2	12
56	Serum Markers of Bone Metastases in Postmenopausal Breast Cancer Patients Treated with Formestane. <i>Tumor Biology</i> , 1997, 18, 197-205.	1.8	4
57	Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 1349-1355.	6.4	20
58	The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997, 63, 261-267.	2.5	33
59	The minimal effective exemestane dose for endocrine activity in advanced breast cancer. <i>European Journal of Cancer</i> , 1997, 33, 587-591.	2.8	38
60	Mucinous Markers in Breast Cancer. <i>Tumori</i> , 1997, 83, 550-551.	1.1	3
61	Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. <i>British Journal of Cancer</i> , 1995, 71, 1111-1114.	6.4	15
62	Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. <i>British Journal of Cancer</i> , 1995, 72, 1007-1012.	6.4	74
63	Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 52, 541-546.	2.5	98
64	Effect of two 4-hydroxyandrostenedione doses on serum insulin-like growth factor I levels in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994, 30, 127-132.	2.5	14
65	Goserelin in Premenopausal Advanced Breast Cancer: Clinical and Endocrine Evaluation of Responsive Patients. <i>Oncology</i> , 1994, 51, 262-269.	1.9	19
66	Urinary testosterone as a marker of risk of recurrence in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 1993, 26, 1-6.	2.5	13